Your browser doesn't support javascript.
loading
Immune repertoire sequencing reveals an abnormal adaptive immune system in COVID-19 survivors.
Jia, Chen; Zhou, Zhiguo; Pan, Wenjing; Zhang, Pan; Yang, Ming; Zhao, Mingming; Li, Bo; Liu, Ping; Zhang, Qianqian; Kong, Xianglong; Li, Keyu; Yue, Tingting; Cai, Ting; Wang, Zijun; De Clercq, Erik; Li, Song; Li, Guangdi; Liu, Jiyang; Wu, Haijing; Lu, Qianjin.
Afiliação
  • Jia C; Hunan Key Laboratory of Medical Epigenomics, Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Zhou Z; The First Hospital of Changsha, Changsha, Hunan Province, China.
  • Pan W; Nanjing ARP Biotechnology Co., Ltd., Nanjing, Jiangsu, China.
  • Zhang P; Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China.
  • Yang M; Hunan Key Laboratory of Medical Epigenomics, Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Zhao M; Hunan Key Laboratory of Medical Epigenomics, Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Li B; The First Hospital of Changsha, Changsha, Hunan Province, China.
  • Liu P; The First Hospital of Changsha, Changsha, Hunan Province, China.
  • Zhang Q; The First Hospital of Changsha, Changsha, Hunan Province, China.
  • Kong X; The First Hospital of Changsha, Changsha, Hunan Province, China.
  • Li K; The First Hospital of Changsha, Changsha, Hunan Province, China.
  • Yue T; Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China.
  • Cai T; Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China.
  • Wang Z; Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • De Clercq E; Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, China.
  • Li S; Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China.
  • Li G; Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
  • Liu J; Hunan Key Laboratory of Biomedical Nanomaterials and Devices, Hunan University of Technology, Zhuzhou, Hunan, China.
  • Wu H; Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China.
  • Lu Q; The First Hospital of Changsha, Changsha, Hunan Province, China.
J Med Virol ; 95(1): e28340, 2023 01.
Article em En | MEDLINE | ID: mdl-36420584
ABSTRACT
Accumulating evidence suggests that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) impairs the adaptive immune system during acute infection. Still, it remains largely unclear whether the frequency and functions of T and B cells return to normal after the recovery of Coronavirus Disease 2019 (COVID-19). Here, we analyzed immune repertoires and SARS-CoV-2-specific neutralization antibodies in a prospective cohort of 40 COVID-19 survivors with a 6-month follow-up after hospital discharge. Immune repertoire sequencing revealed abnormal T- and B-cell expression and function with large T cell receptor/B cell receptor clones, decreased diversity, abnormal class-switch recombination, and somatic hypermutation. A decreased number of B cells but an increased proportion of CD19+ CD138+ B cells were found in COVID-19 survivors. The proportion of CD4+ T cells, especially circulating follicular helper T (cTfh) cells, was increased, whereas the frequency of CD3+ CD4- T cells was decreased. SARS-CoV-2-specific neutralization IgG and IgM antibodies were identified in all survivors, especially those recorded with severe COVID-19 who showed a higher inhibition rate of neutralization antibodies. All severe cases complained of more than one COVID-19 sequelae after 6 months of recovery. Overall, our findings indicate that SARS-CoV-2-specific antibodies remain detectable even after 6 months of recovery. Because of their abnormal adaptive immune system with a low number of CD3+ CD4- T cells and high susceptibility to infections, COVID-19 patients might need more time and medical care to fully recover from immune abnormalities and tissue damage.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Med Virol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Med Virol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China